Ainos Inc. Announces Breakthrough Interim Results in VELDONA Clinical Trial for Feline Chronic Gingivostomatitis, Signaling New Era in Companion Animal Immunotherapy

Reuters
19 May
Ainos Inc. Announces Breakthrough Interim Results in VELDONA Clinical Trial for Feline Chronic Gingivostomatitis, Signaling New Era in Companion Animal Immunotherapy

Ainos Inc., a San Diego-based biotech company, has announced interim results from its ongoing clinical trial of VELDONA, a low-dose oral interferon therapy, for treating Feline Chronic Gingivostomatitis (FCGS), a chronic inflammatory condition in cats. The trial involves 30 cats and aims to assess inflammation scores, corticosteroid usage, and treatment safety. Early results show significant improvements in inflammation and a reduction in steroid dependency. The trial has completed treatment for three cats, all showing clinical improvements without significant side effects. Ainos aims to leverage these findings to strengthen its position in the $13 billion global pet dental health market by offering potential steroid-free or reduced treatments for chronic inflammatory diseases in companion animals. Ainos continues to advance its proprietary AI Nose and VELDONA technologies in its product pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ainos Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1029110) on May 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10